📊 ALXO Key Takeaways
Is Alx Oncology Holdings Inc. (ALXO) a Good Investment?
ALX Oncology is a pre-revenue biotech company with zero commercial sales and negative operating cash flow of -$18.6M, indicating heavy R&D investment burn with no near-term profitability path. While the company maintains a strong balance sheet with $151.3M equity, low debt (0.06x), and $32.3M cash, the fundamental financial model is unsustainable without either successful drug commercialization or significant capital raises; current runway at this burn rate is approximately 18-24 months.
ALX Oncology shows very weak fundamentals: no revenue, persistent operating and net losses, and deeply negative operating and free cash flow. While liquidity ratios are still above 2x and debt is not yet extreme relative to assets, the current cash balance appears small versus the annual cash burn, creating meaningful funding and dilution risk unless the business materially improves its clinical and commercial outlook.
Alx Oncology Holdings Inc. Key Strengths (ALXO)
- Strong balance sheet with $151.3M stockholders' equity and minimal leverage (0.06x debt-to-equity)
- Excellent liquidity position (7.21x current ratio) with $32.3M cash buffer
- Improving cash burn efficiency (EPS improving 26.4% YoY despite losses)
- Current and quick ratios of 2.07x indicate near-term liabilities are still covered by liquid assets
- Debt/equity of 0.39x suggests leverage is not yet the primary balance-sheet problem
- Capital expenditure is minimal, which limits additional cash strain from fixed-asset investment
ALXO Stock Risks: Alx Oncology Holdings Inc. Investment Risks
- Zero revenue and zero path to profitability absent successful drug development and commercialization
- Negative free cash flow of -$18.7M with 18-24 month cash runway at current burn rate, necessitating additional financing
- Extreme execution risk dependent on success of pre-clinical/clinical drug candidates with no near-term revenue catalysts
- Zero revenue means the business currently lacks a proven commercial engine
- Operating cash flow of -$84.14M and free cash flow of -$84.35M imply an unsustainable cash burn relative to $16.37M cash
- ROE of -391.4% and ROA of -172.2% reflect severe capital destruction and weak asset productivity
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and FDA milestone achievements for pipeline candidates
- Capital raise activities and financing needs to extend runway
- Cash runway relative to quarterly operating cash burn
- Any transition from zero revenue toward recurring product or collaboration revenue
Alx Oncology Holdings Inc. (ALXO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.21x current ratio provides a solid financial cushion.
ALXO Profit Margin, ROE & Profitability Analysis
ALXO vs Healthcare Sector: How Alx Oncology Holdings Inc. Compares
How Alx Oncology Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alx Oncology Holdings Inc. Stock Overvalued? ALXO Valuation Analysis 2026
Based on fundamental analysis, Alx Oncology Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alx Oncology Holdings Inc. Balance Sheet: ALXO Debt, Cash & Liquidity
ALXO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alx Oncology Holdings Inc.'s revenue has declined by 75% over the 5-year period, indicating business contraction. The most recent EPS of $-3.74 indicates the company is currently unprofitable.
ALXO Revenue Growth, EPS Growth & YoY Performance
ALXO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $1.2M | -$10.2M | N/A |
| Q2 2021 | $527.0K | -$5.5M | N/A |
| Q1 2021 | $655.0K | -$5.5M | N/A |
| Q3 2020 | $1.2M | -$3.0M | N/A |
| Q2 2020 | $527.0K | -$4.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alx Oncology Holdings Inc. Dividends, Buybacks & Capital Allocation
ALXO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alx Oncology Holdings Inc. (CIK: 0001810182)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALXO
What is the AI rating for ALXO?
Alx Oncology Holdings Inc. (ALXO) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALXO's key strengths?
Claude: Strong balance sheet with $151.3M stockholders' equity and minimal leverage (0.06x debt-to-equity). Excellent liquidity position (7.21x current ratio) with $32.3M cash buffer. ChatGPT: Current and quick ratios of 2.07x indicate near-term liabilities are still covered by liquid assets. Debt/equity of 0.39x suggests leverage is not yet the primary balance-sheet problem.
What are the risks of investing in ALXO?
Claude: Zero revenue and zero path to profitability absent successful drug development and commercialization. Negative free cash flow of -$18.7M with 18-24 month cash runway at current burn rate, necessitating additional financing. ChatGPT: Zero revenue means the business currently lacks a proven commercial engine. Operating cash flow of -$84.14M and free cash flow of -$84.35M imply an unsustainable cash burn relative to $16.37M cash.
What is ALXO's revenue and growth?
Alx Oncology Holdings Inc. reported revenue of $0.0.
Does ALXO pay dividends?
Alx Oncology Holdings Inc. does not currently pay dividends.
Where can I find ALXO SEC filings?
Official SEC filings for Alx Oncology Holdings Inc. (CIK: 0001810182) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALXO's EPS?
Alx Oncology Holdings Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ALXO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Alx Oncology Holdings Inc. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ALXO stock overvalued or undervalued?
Valuation metrics for ALXO: ROE of -11.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ALXO's AI grade for 2026?
Our dual AI analysis gives Alx Oncology Holdings Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALXO's free cash flow?
Alx Oncology Holdings Inc.'s operating cash flow is $-18.6M, with capital expenditures of $50.0K.
How does ALXO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.8% (avg: 15%), current ratio 7.21 (avg: 2).